JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19. https://bit.ly/2NQ15K5

Detalles Bibliográficos
Autores principales: Mehta, Puja, Ciurtin, Coziana, Scully, Marie, Levi, Marcel, Chambers, Rachel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338400/
https://www.ncbi.nlm.nih.gov/pubmed/32631841
http://dx.doi.org/10.1183/13993003.01919-2020
_version_ 1783554666644111360
author Mehta, Puja
Ciurtin, Coziana
Scully, Marie
Levi, Marcel
Chambers, Rachel C.
author_facet Mehta, Puja
Ciurtin, Coziana
Scully, Marie
Levi, Marcel
Chambers, Rachel C.
author_sort Mehta, Puja
collection PubMed
description JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19. https://bit.ly/2NQ15K5
format Online
Article
Text
id pubmed-7338400
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-73384002020-07-13 JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk Mehta, Puja Ciurtin, Coziana Scully, Marie Levi, Marcel Chambers, Rachel C. Eur Respir J Agora JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19. https://bit.ly/2NQ15K5 European Respiratory Society 2020-09-24 /pmc/articles/PMC7338400/ /pubmed/32631841 http://dx.doi.org/10.1183/13993003.01919-2020 Text en Copyright ©ERS 2020 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Agora
Mehta, Puja
Ciurtin, Coziana
Scully, Marie
Levi, Marcel
Chambers, Rachel C.
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
title JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
title_full JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
title_fullStr JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
title_full_unstemmed JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
title_short JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
title_sort jak inhibitors in covid-19: the need for vigilance regarding increased inherent thrombotic risk
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338400/
https://www.ncbi.nlm.nih.gov/pubmed/32631841
http://dx.doi.org/10.1183/13993003.01919-2020
work_keys_str_mv AT mehtapuja jakinhibitorsincovid19theneedforvigilanceregardingincreasedinherentthromboticrisk
AT ciurtincoziana jakinhibitorsincovid19theneedforvigilanceregardingincreasedinherentthromboticrisk
AT scullymarie jakinhibitorsincovid19theneedforvigilanceregardingincreasedinherentthromboticrisk
AT levimarcel jakinhibitorsincovid19theneedforvigilanceregardingincreasedinherentthromboticrisk
AT chambersrachelc jakinhibitorsincovid19theneedforvigilanceregardingincreasedinherentthromboticrisk

Ejemplares similares